Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from CSL ( (AU:CSL) ) is now available.
CSL Limited has announced an update regarding its ongoing share buyback program, with UBS Securities Australia Limited replacing JP Morgan as the broker. This change in broker details signifies a strategic adjustment in the execution of CSL’s buyback plan, potentially impacting its market operations and shareholder value.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$300.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company that operates in the healthcare industry. It specializes in the development and delivery of innovative medicines and vaccines, focusing primarily on rare and serious diseases.
YTD Price Performance: -24.24%
Average Trading Volume: 1,181,759
Technical Sentiment Signal: Sell
Current Market Cap: A$101.5B
Find detailed analytics on CSL stock on TipRanks’ Stock Analysis page.